Press Releases Year None2021202020192018 Nov 26, 2021 Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference Nov 12, 2021 Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment Nov 12, 2021 Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Nov 09, 2021 Akero Therapeutics to Present at the Jefferies London Healthcare Conference Oct 19, 2021 Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH Oct 05, 2021 Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference Sep 07, 2021 Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference Aug 13, 2021 Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Jul 14, 2021 Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors Jul 08, 2021 Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
Year None2021202020192018 Nov 26, 2021 Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference Nov 12, 2021 Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment Nov 12, 2021 Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Nov 09, 2021 Akero Therapeutics to Present at the Jefferies London Healthcare Conference Oct 19, 2021 Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH Oct 05, 2021 Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference Sep 07, 2021 Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference Aug 13, 2021 Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Jul 14, 2021 Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors Jul 08, 2021 Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
Nov 26, 2021 Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference
Nov 12, 2021 Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
Nov 12, 2021 Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Oct 19, 2021 Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
Oct 05, 2021 Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference
Sep 07, 2021 Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference
Aug 13, 2021 Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 08, 2021 Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment
